zk-283197 zk-283197 zk-283197 (also known as bay 86-5310 or sh-t04211c) is a selective and orally active erβ agonist which was under development by bayer healthcare ag for the treatment of vasomotor symptoms. it reached phase ii clinical trials prior to the discontinuation of its development. its development was terminated in 2014. zk-283197clinical dataother namesbay 86-5310; sh-t04211croutes ofadministrationby mouthdrug classestrogen; selective erβ agonistidentifierscas number1644565-93-4